Roche Tecentriq Colon Cancer Milestone: FDA Approves Tecentriq and Tecentriq Hybreza With Chemotherapy for Stage III dMMR Disease
The FDA has approved Tecentriq and Tecentriq Hybreza with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III dMMR colon cancer, based on the phase III ATOMIC trial.
